UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~March~~April 2026

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

In ~~March~~April 2026, Sanofi published the press releases attached hereto as Exhibits 99.1, ~~99.2, 99.3~~ and 99.4 2 which are incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
Exhibit 99.1		Press Release dated ~~March~~April 247, 2026: Sanofi ~~and Regeneron~~’s ~~Dupixent~~lunsekimig ~~approved~~met inprimary ~~Japan~~and askey ~~the~~secondary ~~first~~endpoints ~~targeted~~in ~~medicine~~phase to2 ~~treat~~respiratory ~~adults~~studies ~~with~~in ~~bullous~~asthma ~~pemphigoid~~and CRSwNP
Exhibit 99.2		Press Release dated ~~March~~April 2713, 2026: Sanofi and Regeneron’s ~~Sarclisa~~Dupixent ~~subcutaneous~~approved ~~formulation~~in ~~administered~~the ~~via~~EU ~~on-body~~as ~~injector~~the ~~recommended~~first ~~for~~targeted EUmedicine ~~approval~~to bytreat ~~the~~young ~~CHMP~~children towith ~~treat~~chronic ~~multiple~~spontaneous ~~myeloma~~urticaria
Exhibit 99.3		Press Release dated March 28, 2026: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Exhibit 99.4		Press Release dated March 31, 2026: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 31, 2026	By	SANOFI /s/ Alexandra Roger
Dated: April 15, 2026	By	SANOFI /s/ Alexandra Roger
		Name: Alexandra Roger Title: Head of Legal Corporate & Finance

Filing Compare · Sanofi